Andrew Cooper
Stock Analyst at Raymond James
(2.37)
# 2,303
Out of 4,829 analysts
140
Total ratings
41.94%
Success rate
-2.29%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HAE Haemonetics | Reiterates: Strong Buy | $115 → $105 | $70.26 | +49.44% | 9 | May 9, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.25 | +135.29% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $20.12 | +24.25% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $58.81 | +20.73% | 12 | May 2, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $145 → $120 | $98.50 | +21.83% | 8 | Apr 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $145 → $150 | $120.70 | +24.28% | 2 | Apr 25, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $244.22 | - | 1 | Mar 28, 2025 | |
| GH Guardant Health | Reiterates: Outperform | $39 → $59 | $41.66 | +41.62% | 3 | Feb 21, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $26 → $24 | $13.00 | +84.62% | 14 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $650 → $667 | $432.59 | +54.19% | 6 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $200.83 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $53.40 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.36 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $157.29 | -45.96% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $37.42 | +103.10% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $3.02 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $28.30 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.51 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.76 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.67 | - | 5 | Sep 22, 2021 |
Haemonetics
May 9, 2025
Reiterates: Strong Buy
Price Target: $115 → $105
Current: $70.26
Upside: +49.44%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.25
Upside: +135.29%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $20.12
Upside: +24.25%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $58.81
Upside: +20.73%
Revvity
Apr 29, 2025
Reiterates: Outperform
Price Target: $145 → $120
Current: $98.50
Upside: +21.83%
Integer Holdings
Apr 25, 2025
Maintains: Outperform
Price Target: $145 → $150
Current: $120.70
Upside: +24.28%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $244.22
Upside: -
Guardant Health
Feb 21, 2025
Reiterates: Outperform
Price Target: $39 → $59
Current: $41.66
Upside: +41.62%
Avantor
Feb 10, 2025
Reiterates: Outperform
Price Target: $26 → $24
Current: $13.00
Upside: +84.62%
Thermo Fisher Scientific
Feb 3, 2025
Reiterates: Outperform
Price Target: $650 → $667
Current: $432.59
Upside: +54.19%
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $200.83
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $53.40
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $16.36
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $157.29
Upside: -45.96%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $37.42
Upside: +103.10%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $3.02
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $28.30
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.51
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.76
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.67
Upside: -